



COBAPHARMA API

Creating Value



PRODUCTS

Product	Therapeutic Use	Regulatory Status	
		DMF	CEP
Allopurinol	Antigout	✓	🇪🇺
Apixaban	Anticoagulant	✓	
Apremilast	Psoriatic arthritis	✓	
Azithromycin	Antibiotic	✓	🇪🇺
Bosentan	Arterial hypertension	✓	
Ciprofloxacin	Antibiotic	✓	🇪🇺
Clarithromycin	Antibiotic	✓	🇪🇺
Colistimethate Sodium	Antibiotic	✓	🇪🇺
Dabigatran	Anticoagulant	✓	
Dapagliflozin	Antidiabetic	✓	
Donepezil	Central nervous	✓	
Ezetimibe	Antihyperlipidemic	✓	
Glycopyrronium Bromide	Bronchodilator (COPD)	✓	🇪🇺
Irbesartan	Antihypertensive	✓	🇪🇺
Linagliptin	Antidiabetic	✓	
Memantine HCl	Alzheimer	✓	
Mirabegron	Overactive bladder	✓	
Mirtazapine	Antidepressant	✓	🇪🇺
Naproxen	Anti-inflammatory	✓	🇪🇺
Olmesartan	Antihypertensive	✓	🇪🇺
Omeprazole	Antiulcerative	✓	🇪🇺
Quetiapine	Antipsychotic	✓	🇪🇺
Rivaroxaban	Anticoagulant	✓	
Rosuvastatin	Antihyperlipidemic	✓	🇪🇺
Sofosbuvir	Antiviral	✓	
Solifenacin	Overactive bladder	✓	🇪🇺
Teriflunomide	Multiple sclerosis	✓	
Ticagrelor	Platelet aggregation inhibitor	✓	
Valsartan	Antidiabetic	✓	Filed
Vildagliptin	Antidiabetic	✓	

ONCOLOGY

Product	Therapeutic Use	Regulatory Status	
		DMF	CEP
Dasatinib	Antineoplastic	✓	
Gefitinib	Antineoplastic	✓	
Exemestane	Antineoplastic	✓	🇪🇺
Lenalidomide	Antineoplastic	✓	

None of the products will be offered / supplied to countries in which this could be in conflict with existing patents. However, the final responsibility lies exclusively with the buyer. Patented products available for R&D use as permitted under 35 USC 271 (e) (1).

CONTROLLED SUBSTANCES

Product	Therapeutic Use	Regulatory Status	
		DMF	CEP
Methadone	Opioid dependence	✓	🇪🇺
Methylphenidate	Central nervous	✓	🇪🇺
Phenobarbital	Anticonvulsant	✓	🇪🇺

CEPHALOSPORINS

Product	Therapeutic Use	Regulatory Status	
		DMF	CEP
Cefazolin Sodium	Antibiotic	✓	🇪🇺
Cefditoren Pivoxil	Antibiotic	R&D	
Cefepime Dihydrochloride	Antibiotic	✓	🇪🇺
Cefixime	Antibiotic	✓	🇪🇺
Cefoxitin	Antibiotic	R&D	
Ceftazidime	Antibiotic	✓	🇪🇺
Ceftriaxone Sodium	Antibiotic	✓	🇪🇺
Cefuroxime Sodium	Antibiotic	✓	🇪🇺

UNDER DEVELOPMENT PRODUCTS

Product	Therapeutic Use	Regulatory Status
		DMF
Betrixaban	Venous Thromboembolism	Q2 2020
Brexiprazole	Depression, Schizophrenia	Q1 2020
Canagliflozin	Antidiabetic	Q1 2020
Edoxaban	Anticoagulant	Q2 2020
Empagliflozin	Antidiabetic	Q2 2019
Indacaterol	Bronchodilator (COPD)	Q3 2020
Macitentan	Pulmonary hypertension	Q1 2020
Sacubitril / Valsartan	Antihypertensive	Q4 2019
Trelagliptin	Antidiabetic	Q4 2019
Varenicline	Antismoking	Q1 2020
Vortioxetine	Depression	Q3 2019
Tofacitinib	Antineoplastic	Q4 2019

None of the products will be offered / supplied to countries in which this could be in conflict with existing patents. However, the final responsibility lies exclusively with the buyer. Patented products available for R&D use as permitted under 35 USC 271 (e) (1).



COBAPHARMA

C/ Rosselló, 34, 1º 2ª
08029, Barcelona, Spain
Tel: +34 93 355 49 15
www.cobapharma.com



Certificate Number
CERT7205CBPEB

